<DOC>
	<DOCNO>NCT00896454</DOCNO>
	<brief_summary>The purpose study determine potential denosumab treat Hypercalcemia Malignancy patient elevate serum calcium respond recent treatment intravenous bisphosphonates lower correct serum calcium &lt; /= 11.5 mg/dL ( 2.9 millimoles /L ) day 10 .</brief_summary>
	<brief_title>Study Denosumab Treatment Hypercalcemia Malignancy Subjects With Elevated Serum Calcium</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Hypercalcemia</mesh_term>
	<mesh_term>Paraneoplastic Syndromes</mesh_term>
	<mesh_term>Parathyroid Neoplasms</mesh_term>
	<mesh_term>Endocrine Gland Neoplasms</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Hypercalcemia Malignancy ( HCM ) define document histologically cytologically confirm cancer correct serum calcium ( CSC ) &gt; 12.5 mg/dL ( 3.1 millimoles /L ) screen local laboratory Last IV bisphosphonate treatment must &gt; /= 7 day &lt; /= 30 day screen correct serum calcium Adults ( &gt; /=18 year ) Adequate organ function define follow criterion : serum aspartate aminotransferase ( AST ) &lt; /= 5 x upper limit normal ( ULN ) serum alanine aminotransferase ( ALT ) &lt; /= 5 x upper limit normal serum total bilirubin &lt; /= 2 x upper limit normal Evidence benign hyperparathyroidism , hyperthyroidism , adrenal insufficiency , vitamin D intoxication , milk alkali syndrome , sarcoidosis , granulomatous disease Receiving dialysis renal failure Treatment thiazide , calcitonin , mithramycin , gallium nitrate within window expect therapeutic effect ( determined physician ) prior date screen CSC Treatment cinacalcet within 4 week prior date screen CSC Thirty day less since receive investigational product ( denosumab ) device ( ie , marketing authorization ; thalidomide use allow ) another clinical study Known sensitivity product administer study ( eg , mammalian derive product ) Female subject pregnant breast feeding , plan become pregnant within 7 month end treatment Female subject childbearing potential willing use 2 highly effective method contraception treatment 7 month end treatment Subject available followup assessment . Any organic psychiatric disorder , opinion investigator , might prevent subject complete study interfere interpretation study result</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>hypercalcemia</keyword>
	<keyword>calcium</keyword>
	<keyword>bisphosphonates</keyword>
	<keyword>denosumab</keyword>
	<keyword>amgen</keyword>
	<keyword>malignancy</keyword>
	<keyword>20070315</keyword>
	<keyword>HMC</keyword>
	<keyword>oncology</keyword>
	<keyword>hematology</keyword>
</DOC>